| Index | — | P/E | 19.94 | EPS (ttm) | 1.35 | Insider Own | — | Shs Outstand | 972.54M | Perf Week | 0.11% |
| Market Cap | 26.18B | Forward P/E | 14.25 | EPS next Y | 1.89 | Insider Trans | — | Shs Float | 971.67M | Perf Month | 13.06% |
| Enterprise Value | 32.66B | PEG | 2.86 | EPS next Q | 0.41 | Short Float | 0.29% | Perf Quarter | 2.63% | ||
| Income | 1.30B | P/S | 1.27 | EPS this Y | 16.30% | Short Ratio | 2.64 | Perf Half Y | 2.91% | ||
| Sales | 20.60B | P/B | 2.00 | EPS next Y | 2.20% | ROA | 4.17% | Short Interest | 2.79M | Perf YTD | -0.59% |
| Book/sh | 13.47 | P/C | 12.82 | EPS next 5Y | 6.98% | ROE | 10.05% | 52W High | 33.44 -19.50% | Perf Year | -2.46% |
| Cash/sh | 2.10 | P/FCF | 11.80 | EPS past 3/5Y | — -5.64% | ROIC | 6.63% | 52W Low | 23.62 13.97% | Perf 3Y | 52.78% |
| Dividend Est. | 0.99 (3.68%) | EV/EBITDA | 9.19 | Sales past 3/5Y | 2.38% 0.38% | Gross Margin | 45.93% | Volatility | 1.50% 1.52% | Perf 5Y | -39.49% |
| Dividend TTM | 0.99 (3.68%) | EV/Sales | 1.59 | EPS Y/Y TTM | 564.78% | Oper. Margin | 10.17% | ATR (14) | 0.46 | Perf 10Y | 3.54% |
| Dividend Ex-Date | May 13, 2026 | Quick Ratio | 0.82 | Sales Y/Y TTM | 6.13% | Profit Margin | 6.31% | RSI (14) | 65.39 | Recom | 2.64 |
| Dividend Gr. 3/5Y | 0.11% 3.87% | Current Ratio | 1.26 | EPS Q/Q | 39.02% | SMA20 | 5.13% | Beta | 0.71 | Target Price | — |
| Payout | 31.78% | Debt/Eq | 0.65 | Sales Q/Q | 3.07% | SMA50 | 5.48% | Rel Volume | 1.32 | Prev Close | 27.12 |
| Employees | 66,401 | LT Debt/Eq | 0.55 | Earnings | Nov 03 | SMA200 | -1.06% | Avg Volume | 964.24K | Price | 26.92 |
| IPO Date | Mar 17, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 39.63% -0.42% | Net Debt/EBITDA | 1.82 | Volume | 1,273,375 | Change | -0.74% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-03-26 | Downgrade | UBS | Buy → Neutral | |
| Feb-20-25 | Upgrade | UBS | Neutral → Buy | |
| Oct-29-24 | Upgrade | Jefferies | Underperform → Hold | |
| May-13-24 | Upgrade | Bernstein | Market Perform → Outperform | |
| Apr-30-24 | Upgrade | JP Morgan | Underweight → Neutral | |
| Apr-30-24 | Upgrade | UBS | Sell → Neutral | |
| Jul-25-22 | Downgrade | Societe Generale | Buy → Hold | |
| Jan-20-22 | Downgrade | Jefferies | Buy → Hold | |
| Jan-14-22 | Upgrade | HSBC | Hold → Buy | |
| Jan-12-22 | Downgrade | Citigroup | Buy → Neutral |
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20,602 | 20,119 | 19,497 | 19,652 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 11,141 | 11,029 | 11,087 | 11,596 | — | — | — | — | — | |
| Gross Profit | 9,463 | 9,091 | 8,410 | 8,056 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 5,685 | 5,607 | 5,483 | 5,551 | — | — | — | — | — | |
| Research and Development | 2,005 | 1,918 | 1,890 | 2,044 | — | — | — | — | — | |
| Other Operating Expense | -234 | -41 | 464 | 585 | — | — | — | — | — | |
| Operating Income | 2,006 | 1,606 | 572 | -124 | — | — | — | — | — | |
| Interest Expense | 424 | 375 | 365 | 331 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 140 | 102 | -75 | -115 | — | — | — | — | — | |
| Net Income Before Taxes | 1,721 | 1,333 | 133 | -570 | — | — | — | — | — | |
| Income Taxes | 425 | 318 | 1,042 | -79 | — | — | — | — | — | |
| Consolidated Net Income | 1,298 | 1,010 | -759 | -504 | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,298 | 1,015 | -909 | -491 | — | — | — | — | — | |
| Net Income | 1,298 | 1,010 | -759 | -504 | — | — | — | — | — | |
| EPS (Recurring) | 1.35 | 1.07 | -0.81 | -0.53 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.35 | 1.07 | -0.81 | -0.53 | — | — | — | — | — | |
| EPS (Diluted) | 1.35 | 1.05 | -0.81 | -0.53 | — | — | — | — | — | |
| EBITDA | 3,553 | 2,978 | 2,000 | 1,126 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 19.94 | 25.81 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.25 | 1.29 | 1.21 | 1.09 | — | — | — | — | — | |
| Gross Margin | 45.93 | 45.19 | 43.13 | 40.99 | — | — | — | — | — | |
| Operating Margin | 9.74 | 7.98 | 2.93 | -0.63 | — | — | — | — | — | |
| Net Margin | 6.30 | 5.02 | -3.89 | -2.56 | — | — | — | — | — | |
| Shares Outstanding | 956 | 962 | 933 | 949 | — | — | — | — | — | |
| Market Capitalization | 25,736 | 26,051 | 23,624 | 21,409 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |